Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are male or female aged 18-75 years at the time of signing the informed consent form.~* Have been diagnosed as having RA according to the revised 1987 American College of Rheumatology (ACR) criteria for at least 6 months but not exceeding 15 years prior to Screening.~* Have moderate to severe active disease despite MTX therapy defined as:~  1. More than or equal to six swollen joints and more than or equal to six tender joints (from the 66/68 joint count system) at Screening and Randomisation.~ 2. Either erythrocyte sedimentation rate (Westergren) ≥ 28 mm/h or serum C-reactive protein ≥ 10 mg/dL at Screening.~* Must have been treated with MTX for a total of at least 6 months prior to Randomisation and must have been on both: a stable route of administration (oral or parenteral) and stable dose of MTX (10-25 mg/week) for at least 4 weeks prior to Screening.~* Female subjects who are not pregnant or nursing at Screening and Randomisation and who are not planning to become pregnant from Screening until 5 months after the last dose of IP.~Exclusion Criteria:~* Have been treated previously with any biological agents including any tumour necrosis factor inhibitor.~* Have a known hypersensitivity to human immunoglobulin proteins or other components of Humira or SB5.~* Have a positive serological test for hepatitis B or hepatitis C or have a known history of infection with human immunodeficiency virus.~* Have a current diagnosis of active tuberculosis (TB), have been recently exposed to a person with active TB, or are considered to have latent TB.~* Have had a serious infection or have been treated with intravenous antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Randomisation.~* Have a history of chronic or recurrent infection.~* Have any of the following conditions:~  1. History of congestive heart failure (New York Heart Association Class III/IV).~ 2. History of acute myocardial infarction or unstable angina within the previous 12 months prior to Screening.~ 3. History of demyelinating disorders.~ 4. History of any malignancy within the previous 5 years prior to Screening.~ 5. History of lymphoproliferative disease including lymphoma.~ 6. Any other disease or disorder which, in the opinion of the Investigator, will put the subject at risk if they are enrolled.~* Have physical incapacitation (ACR functional Class IV or wheelchair-/bed-bound).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- SB5 (proposed biosimilar to adalimumab) (Type: EXPERIMENTAL): SB5 40 mg every other week via subcutaneous injection
- Humira (adalimumab) (Type: ACTIVE_COMPARATOR): Humira 40 mg every other week via subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).